Cardiac Assist Devices (CAD) Global Market - Forecast to 2027
Cardiac Assist Devices (CAD) Global Market - Forecast to 2027
Abstract
Cardiac Assist Devices (CAD) Global Market Overview:
The heart conditions are considered advanced or end-stage heart failure when conventional heart therapies and management strategies no longer work. The reduced ability of the heart to pump blood and maintain normal bodily function leads to heart failure. Heart transplantation is currently the preferred treatment for end-stage heart failure.
The availability of donor heart is insufficient to meet the required demand and many patients are not eligible for transplantation due to age and other health conditions. The Cardiac assist devices (CAD) i.e., Ventricular Assist Devices (VAD), Total Artificial Heart (TAH), and Intra-Aortic Balloon Pump (IABP) are used to treat various conditions related to the heart such as end-stage heart failure, refractory angina pectoris, post-cardiopulmonary bypass shock, myocardial infarction, myocarditis and others. The ventricular assist device is a mechanical pump that supports heart function and blood flow by reducing the workload of the left ventricle, right ventricle, or both left and right ventricles helping the heart to pump oxygenated blood to the rest of the body.
The indication for VAD use is acute cardiogenic shock (post-cardiac surgery, myocarditis, and massive myocardial infarction) and chronic heart failure. Percutaneous Ventricular Assist Devices (PVADs) to provide hemodynamic support in patients undergoing high-risk percutaneous coronary intervention (PCI). PVADs are often used as temporary support in left ventricular failure patients who are assisted for LVAD implantation.
An artificial heart (TAH) is a mechanical assist device for people with biventricular heart failure and heart transplant candidate which replaces both native ventricles and all four chambers of the heart, thereby eliminating the symptoms of cardiac insufficiency or heart failure. Intra-aortic balloon pump (IABP) is placed in the aorta to help the heart to pump more blood by reducing the workload on the heart and improves the function of the left ventricle as this is the chamber that pumps blood into the aorta. IABP is used in conditions such as acute mitral valve regurgitation or severe heart failure, left ventricular failure, unstable angina and others.
According to IQ4I Analysis, the Cardiac Assist Devices (CAD) Global Market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $4,813.5 million by 2027. Cardiac Assist Devices based on product type are segmented into Ventricular assist device (VAD), Total Artificial Heart (TAH), and Intra-Aortic Balloon Pump (IABP) among which VAD commanded the largest share in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027.
Ventricular assist device is sub-segmented into Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), and Biventricular Assist Devices (Bi-VAD). Among this, LVAD commanded the largest revenue in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027. CAD market based on pump type is segmented into Pulsatile Pump and Continuous Flow Pump, among which, continuous flow pump segment commanded the largest share in 2020 and is expected to grow at double digit CAGR from 2020 to 2027.
The continuous flow pump is further segmented into axial flow pump and Centrifugal flow pump, the axial flow pump generated the largest revenue in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027. CAD market based on implant type is segmented into Extracorporeal CAD, Intracorporeal CAD, and Percutaneous CAD, among these, percutaneous CAD generated the largest revenue in 2020 and is expected grow at a strong double digit CAGR from 2020 to 2027.
Cardiac Assist Devices (CAD) Global Market based on patient type is segmented into Adult and Pediatric, among which, adult market commanded the largest revenue in 2020. The CAD application market is classified as Bridge to Transplant (BTT), Bridge to destination (BTD), Bridge to Recovery (BTR), and Bridge to Candidacy (BTC) among which Bridge to recovery (BTR) commanded the largest share in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027.
Some of the key players of the Cardiac assist devices are Abbott Laboratories (U.S.), Medtronic PLC (Ireland), Abiomed, Inc (U.S.), Reliant Heart, Inc (U.S.), Fresenius Medical Care AG & Co. KGaA Care AG & Co. KGaA (Germany), Getinge Group (Sweden), Syncardia Systems LLC (U.S.), Zeon Corporation (Japan), Teleflex Incorporated (U.S.) and others.
Content
1 EXECUTIVE SUMMARY 21
2 INTRODUCTION 27
2.1 KEY TAKEAWAYS 27
2.2 REPORT DESCRIPTION 28
2.3 MARKETS COVERED 30
2.4 STAKEHOLDERS 31
2.5 RESEARCH METHODOLOGY 32
2.5.1 MARKET SIZE ESTIMATION 33
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.5.3 SECONDARY SOURCES 37
2.5.4 PRIMARY SOURCES 38
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 38
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 39
2.5.7 ASSUMPTIONS 40
3 MARKET ANALYSIS 42
3.1 INTRODUCTION 42
3.2 MARKET SEGMENTATION 43
3.3 FACTORS INFLUENCING MARKET 45
3.3.1 DRIVERS AND OPPORTUNITIES 45
3.3.1.1 Increasing incidence of heart failure 45
3.3.1.2 Shortage of heart donors 46
3.3.1.3 Technological advancements in CAD 47
3.3.1.4 Rising geriatric population 48
3.3.1.5 Vast pipeline products 49
3.3.1.6 Increase in funding for CAD research 51
3.3.2 RESTRAINTS AND THREATS 52
3.3.2.1 Adverse events and complication with the implantations of CAD 52
3.3.2.2 Cost of the devices 53
3.3.2.3 Lack of skilled and trained professionals 54
3.3.2.4 Stringent regulatory guidelines 55
3.3.2.5 Availability of alternative products 56
3.4 REGULATORY AFFAIRS 56
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 57
3.4.1.1 ISO 9001: 2015 Quality Management System 57
3.4.1.2 ISO 14644-1 Cleanroom Standards 57
3.4.1.3 ISO 13485 Medical Devices 58
3.4.1.4 ISO 10993 Biological Evaluation Of Medical Devices 58
3.4.1.5 ISO 14971: Risk Management Of Medical Devices 59
3.4.1.6 ISO 14708-5: Active Implantable Medical Devices - Part 5: Circulatory
Support Devices 59
3.4.1.7 IEC 60601-1 Medical Electrical Equipment Standard 59
3.4.1.8 IEC 60601-1-11 Home Care Safety 60
3.4.2 U.S. 60
3.4.3 CANADA 61
3.4.4 EUROPE 61
3.4.5 CHINA 62
3.4.6 JAPAN 64
3.4.7 INDIA 65
3.5 REIMBURSEMENT SCENARIO 66
3.5.1 REIMBURSEMENT TABLE 68
3.5.1.1 Ventricular assist device reimbursement 68
3.5.1.2 CAD physician reimbursement 68
3.6 FUNDING SCENARIO 71
3.7 UPCOMING TECHNOLOGY 76
3.8 CLINICAL TRIAL DATA 79
3.9 PATENT TRENDS 85
3.10 TECHNOLOGICAL ADVANCEMENTS 87
3.10.1 INTRODUCTION 87
3.10.2 EXTRA AORTIC BALLOON PUMP 87
3.10.3 NON-BLOOD-CONTACTING CADS 88
3.10.4 MUSCLE POWERED VADS 88
3.11 PORTER’S FIVE FORCE ANALYSIS 89
3.11.1 THREAT OF NEW ENTRANTS 90
3.11.2 THREAT OF SUBSTITUTES 91
3.11.3 BARGAINING POWER OF SUPPLIERS 92
3.11.4 BARGAINING POWER OF BUYERS 92
3.11.5 COMPETITIVE RIVALRY 93
3.12 PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION 94
3.12.1 U.S. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 94
3.12.2 U.K. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 95
3.12.3 GERMANY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 96
3.12.4 FRANCE PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 97
3.12.5 JAPAN PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 98
3.13 INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION 99
3.13.1 U.S. INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 100
3.13.2 U.K. INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 101
3.13.3 GERMANY INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 102
3.13.4 FRANCE INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 103
3.13.5 JAPAN INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 104
3.14 SUPPLY CHAIN ANALYSIS 105
3.15 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 111
3.15.1 CARDIAC ASSIST DEVICES (CAD) GLOBAL MARKET SHARE ANALYSIS 111
3.15.2 VENTRICULAR ASSIST DEVICES (VAD) GLOBAL MARKET SHARE
ANALYSIS 114
3.15.3 INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE
ANALYSIS 116
3.16 CARDIAC ASSIST DEVICES NUMBER OF UNITS SOLD BY REGION 118
3.16.1 VENTRICULAR ASSIST DEVICES NUMBER OF UNITS SOLD BY REGION 118
3.16.1.1 Ventricular Assist Devices (VAD) number of units sold 119
3.16.1.2 Percutaneous Ventricular Assist Devices number of units sold 120
3.16.2 IABP DEVICES GLOBAL NUMBER OF UNITS SOLD BY REGION 121
3.16.3 TOTAL ARTIFICIAL HEART NUMBER OF UNITS BY REGION 122
3.16.4 COMPANYWISE VAD NUMBER OF UNITS SOLD (2020) 123
3.17 COMPARISON OF CARDIAC ASSIST DEVICES 123
4 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PRODUCT 131
4.1 INTRODUCTION 131
4.2 VENTRICULAR ASSIST DEVICES (VAD) 135
4.2.1 LEFT VENTRICULAR ASSIST DEVICES (LVAD) 143
4.2.2 RIGHT VENTRICULAR ASSIST DEVICES (RVAD) 145
4.2.3 BI-VENTRICULAR ASSIST DEVICES (BI-VAD) 147
4.3 INTRA-AORTIC BALLOON PUMPS (IABP) 149
4.4 TOTAL ARTIFICIAL HEART (TAH) 150
5 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY IMPLANT TYPE 153
5.1 INTRODUCTION 153
5.2 EXTRACORPOREAL OR PARACORPOREAL CAD 155
5.3 INTRACORPOREAL CAD 157
5.4 PERCUTANEOUS CAD 159
6 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PUMP TYPE 162
6.1 INTRODUCTION 162
6.2 PULSATILE FLOW PUMP 165
6.3 CONTINUOUS FLOW PUMP 167
6.3.1 CENTRIFUGAL FLOW PUMP 171
6.3.2 AXIAL FLOW PUMP 173
7 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PATIENT TYPE 175
7.1 INTRODUCTION 175
7.2 PEDIATRIC CAD 177
7.3 ADULT CAD 180
8 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY APPLICATION 182
8.1 INTRODUCTION 182
8.2 CAD TREATMENT FLOW CHART 185
8.3 BRIDGE TO TRANSPLANT (BTT) 187
8.4 BRIDGE TO DESTINATION THERAPY (BTD) 188
8.5 BRIDGE TO RECOVERY (BTR) 190
8.6 BRIDGE TO CANDIDACY (BTC) 191
9 REGIONAL ANALYSIS 193
9.1 INTRODUCTION 193
9.2 NORTH AMERICA 196
9.2.1 THE U.S. 211
9.2.2 REST OF NORTH AMERICA 216
9.3 EUROPE 220
9.3.1 GERMANY 237
9.3.2 FRANCE 242
9.3.3 U.K. 246
9.3.4 REST OF EUROPE 250
9.4 APAC 255
9.4.1 JAPAN 271
9.4.2 CHINA 276
9.4.3 INDIA 281
9.4.4 REST OF APAC 286
9.5 ROW 291
9.5.1 BRAZIL 307
9.5.2 REST OF LATIN AMERICA 311
9.5.3 MIDDLE EAST AND OTHERS 316
10 COMPANY DEVELOPMENTS 321
10.1 INTRODUCTION 321
10.2 APPROVALS 322
10.3 AGREEMENTS AND JOINT VENTURES 324
10.4 OTHER DEVELOPMENTS 324
11 MAJOR COMPANIES 326
11.1 ABBOTT LABORATORIES 326
11.1.1 OVERVIEW 326
11.1.2 FINANCIALS 327
11.1.3 PRODUCT PORTFOLIO 329
11.1.4 KEY DEVELOPMENTS 330
11.1.5 BUSINESS STRATEGY 330
11.1.6 SWOT ANALYSIS 331
11.2 ABIOMED, INC. 332
11.2.1 OVERVIEW 332
11.2.2 FINANCIALS 333
11.2.3 PRODUCT PORTFOLIO 334
11.2.4 KEY DEVELOPMENTS 334
11.2.5 BUSINESS STRATEGY 335
11.2.6 SWOT ANALYSIS 336
11.3 BERLIN HEART GMBH 337
11.3.1 OVERVIEW 337
11.3.2 FINANCIALS 337
11.3.3 PRODUCT PORTFOLIO 338
11.3.4 KEY DEVELOPMENTS 338
11.3.5 BUSINESS STRATEGY 339
11.3.6 SWOT ANALYSIS 340
11.4 FRESENIUS MEDICAL CARE AG & CO. KGAA (XENIOS AG) 341
11.4.1 OVERVIEW 341
11.4.2 FINANCIALS 342
11.4.3 PRODUCT PORTFOLIO 343
11.4.4 KEY DEVELOPMENTS 344
11.4.5 BUSINESS STRATEGY 344
11.4.6 SWOT ANALYSIS 345
11.5 GETINGE GROUP (MAQUET) 346
11.5.1 OVERVIEW 346
11.5.2 FINANCIALS 347
11.5.3 PRODUCT PORTFOLIO 348
11.5.4 KEY DEVELOPMENTS 349
11.5.5 BUSINESS STRATEGY 349
11.5.6 SWOT ANALYSIS 350
11.6 LIVANOVA PLC 351
11.6.1 OVERVIEW 351
11.6.2 FINANCIALS 352
11.6.3 PRODUCT PORTFOLIO 354
11.6.4 KEY DEVELOPMENTS 354
11.6.5 BUSINESS STRATEGY 355
11.6.6 SWOT ANALYSIS 356
11.7 MEDTRONIC, PLC 357
11.7.1 OVERVIEW 357
11.7.2 FINANCIALS 358
11.7.3 PRODUCT PORTFOLIO 361
11.7.4 KEY DEVELOPMENTS 362
11.7.5 BUSINESS STRATEGY 362
11.7.6 SWOT ANALYSIS 363
11.8 SYNCARDIA SYSTEMS, LLC 364
11.8.1 OVERVIEW 364
11.8.2 FINANCIALS 365
11.8.3 PRODUCT PORTFOLIO 365
11.8.4 KEY DEVELOPMENTS 365
11.8.5 BUSINESS STRATEGY 365
11.8.6 SWOT ANALYSIS 366
11.9 TELEFLEX INCORPORATED 367
11.9.1 OVERVIEW 367
11.9.2 FINANCIALS 368
11.9.3 PRODUCT PORTFOLIO 371
11.9.4 KEY DEVELOPMENTS 371
11.9.5 BUSINESS STRATEGY 371
11.9.6 SWOT ANALYSIS 372
11.10 ZEON CORPORATION 373
11.10.1 OVERVIEW 373
11.10.2 FINANCIALS 374
11.10.3 PRODUCT PORTFOLIO 376
11.10.4 KEY DEVELOPMENTS 376
11.10.5 BUSINESS STRATEGY 377
11.10.6 SWOT ANALYSIS 378
Cardiac Assist Devices (CAD) Global Market Overview:
The heart conditions are considered advanced or end-stage heart failure when conventional heart therapies and management strategies no longer work. The reduced ability of the heart to pump blood and maintain normal bodily function leads to heart failure. Heart transplantation is currently the preferred treatment for end-stage heart failure.
The availability of donor heart is insufficient to meet the required demand and many patients are not eligible for transplantation due to age and other health conditions. The Cardiac assist devices (CAD) i.e., Ventricular Assist Devices (VAD), Total Artificial Heart (TAH), and Intra-Aortic Balloon Pump (IABP) are used to treat various conditions related to the heart such as end-stage heart failure, refractory angina pectoris, post-cardiopulmonary bypass shock, myocardial infarction, myocarditis and others. The ventricular assist device is a mechanical pump that supports heart function and blood flow by reducing the workload of the left ventricle, right ventricle, or both left and right ventricles helping the heart to pump oxygenated blood to the rest of the body.
The indication for VAD use is acute cardiogenic shock (post-cardiac surgery, myocarditis, and massive myocardial infarction) and chronic heart failure. Percutaneous Ventricular Assist Devices (PVADs) to provide hemodynamic support in patients undergoing high-risk percutaneous coronary intervention (PCI). PVADs are often used as temporary support in left ventricular failure patients who are assisted for LVAD implantation.
An artificial heart (TAH) is a mechanical assist device for people with biventricular heart failure and heart transplant candidate which replaces both native ventricles and all four chambers of the heart, thereby eliminating the symptoms of cardiac insufficiency or heart failure. Intra-aortic balloon pump (IABP) is placed in the aorta to help the heart to pump more blood by reducing the workload on the heart and improves the function of the left ventricle as this is the chamber that pumps blood into the aorta. IABP is used in conditions such as acute mitral valve regurgitation or severe heart failure, left ventricular failure, unstable angina and others.
According to IQ4I Analysis, the Cardiac Assist Devices (CAD) Global Market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $4,813.5 million by 2027. Cardiac Assist Devices based on product type are segmented into Ventricular assist device (VAD), Total Artificial Heart (TAH), and Intra-Aortic Balloon Pump (IABP) among which VAD commanded the largest share in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027.
Ventricular assist device is sub-segmented into Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), and Biventricular Assist Devices (Bi-VAD). Among this, LVAD commanded the largest revenue in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027. CAD market based on pump type is segmented into Pulsatile Pump and Continuous Flow Pump, among which, continuous flow pump segment commanded the largest share in 2020 and is expected to grow at double digit CAGR from 2020 to 2027.
The continuous flow pump is further segmented into axial flow pump and Centrifugal flow pump, the axial flow pump generated the largest revenue in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027. CAD market based on implant type is segmented into Extracorporeal CAD, Intracorporeal CAD, and Percutaneous CAD, among these, percutaneous CAD generated the largest revenue in 2020 and is expected grow at a strong double digit CAGR from 2020 to 2027.
Cardiac Assist Devices (CAD) Global Market based on patient type is segmented into Adult and Pediatric, among which, adult market commanded the largest revenue in 2020. The CAD application market is classified as Bridge to Transplant (BTT), Bridge to destination (BTD), Bridge to Recovery (BTR), and Bridge to Candidacy (BTC) among which Bridge to recovery (BTR) commanded the largest share in 2020 and is expected to grow at a strong double digit CAGR from 2020 to 2027.
Some of the key players of the Cardiac assist devices are Abbott Laboratories (U.S.), Medtronic PLC (Ireland), Abiomed, Inc (U.S.), Reliant Heart, Inc (U.S.), Fresenius Medical Care AG & Co. KGaA Care AG & Co. KGaA (Germany), Getinge Group (Sweden), Syncardia Systems LLC (U.S.), Zeon Corporation (Japan), Teleflex Incorporated (U.S.) and others.
1 EXECUTIVE SUMMARY 21
2 INTRODUCTION 27
2.1 KEY TAKEAWAYS 27
2.2 REPORT DESCRIPTION 28
2.3 MARKETS COVERED 30
2.4 STAKEHOLDERS 31
2.5 RESEARCH METHODOLOGY 32
2.5.1 MARKET SIZE ESTIMATION 33
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.5.3 SECONDARY SOURCES 37
2.5.4 PRIMARY SOURCES 38
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 38
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 39
2.5.7 ASSUMPTIONS 40
3 MARKET ANALYSIS 42
3.1 INTRODUCTION 42
3.2 MARKET SEGMENTATION 43
3.3 FACTORS INFLUENCING MARKET 45
3.3.1 DRIVERS AND OPPORTUNITIES 45
3.3.1.1 Increasing incidence of heart failure 45
3.3.1.2 Shortage of heart donors 46
3.3.1.3 Technological advancements in CAD 47
3.3.1.4 Rising geriatric population 48
3.3.1.5 Vast pipeline products 49
3.3.1.6 Increase in funding for CAD research 51
3.3.2 RESTRAINTS AND THREATS 52
3.3.2.1 Adverse events and complication with the implantations of CAD 52
3.3.2.2 Cost of the devices 53
3.3.2.3 Lack of skilled and trained professionals 54
3.3.2.4 Stringent regulatory guidelines 55
3.3.2.5 Availability of alternative products 56
3.4 REGULATORY AFFAIRS 56
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 57
3.4.1.1 ISO 9001: 2015 Quality Management System 57
3.4.1.2 ISO 14644-1 Cleanroom Standards 57
3.4.1.3 ISO 13485 Medical Devices 58
3.4.1.4 ISO 10993 Biological Evaluation Of Medical Devices 58
3.4.1.5 ISO 14971: Risk Management Of Medical Devices 59
3.4.1.6 ISO 14708-5: Active Implantable Medical Devices - Part 5: Circulatory
Support Devices 59
3.4.1.7 IEC 60601-1 Medical Electrical Equipment Standard 59
3.4.1.8 IEC 60601-1-11 Home Care Safety 60
3.4.2 U.S. 60
3.4.3 CANADA 61
3.4.4 EUROPE 61
3.4.5 CHINA 62
3.4.6 JAPAN 64
3.4.7 INDIA 65
3.5 REIMBURSEMENT SCENARIO 66
3.5.1 REIMBURSEMENT TABLE 68
3.5.1.1 Ventricular assist device reimbursement 68
3.5.1.2 CAD physician reimbursement 68
3.6 FUNDING SCENARIO 71
3.7 UPCOMING TECHNOLOGY 76
3.8 CLINICAL TRIAL DATA 79
3.9 PATENT TRENDS 85
3.10 TECHNOLOGICAL ADVANCEMENTS 87
3.10.1 INTRODUCTION 87
3.10.2 EXTRA AORTIC BALLOON PUMP 87
3.10.3 NON-BLOOD-CONTACTING CADS 88
3.10.4 MUSCLE POWERED VADS 88
3.11 PORTER’S FIVE FORCE ANALYSIS 89
3.11.1 THREAT OF NEW ENTRANTS 90
3.11.2 THREAT OF SUBSTITUTES 91
3.11.3 BARGAINING POWER OF SUPPLIERS 92
3.11.4 BARGAINING POWER OF BUYERS 92
3.11.5 COMPETITIVE RIVALRY 93
3.12 PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION 94
3.12.1 U.S. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 94
3.12.2 U.K. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 95
3.12.3 GERMANY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 96
3.12.4 FRANCE PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 97
3.12.5 JAPAN PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS 98
3.13 INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION 99
3.13.1 U.S. INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 100
3.13.2 U.K. INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 101
3.13.3 GERMANY INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 102
3.13.4 FRANCE INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 103
3.13.5 JAPAN INTRA-AORTIC BALLOON PUMP (IABP) MARKET PENETRATION ANALYSIS 104
3.14 SUPPLY CHAIN ANALYSIS 105
3.15 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 111
3.15.1 CARDIAC ASSIST DEVICES (CAD) GLOBAL MARKET SHARE ANALYSIS 111
3.15.2 VENTRICULAR ASSIST DEVICES (VAD) GLOBAL MARKET SHARE
ANALYSIS 114
3.15.3 INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE
ANALYSIS 116
3.16 CARDIAC ASSIST DEVICES NUMBER OF UNITS SOLD BY REGION 118
3.16.1 VENTRICULAR ASSIST DEVICES NUMBER OF UNITS SOLD BY REGION 118
3.16.1.1 Ventricular Assist Devices (VAD) number of units sold 119
3.16.1.2 Percutaneous Ventricular Assist Devices number of units sold 120
3.16.2 IABP DEVICES GLOBAL NUMBER OF UNITS SOLD BY REGION 121
3.16.3 TOTAL ARTIFICIAL HEART NUMBER OF UNITS BY REGION 122
3.16.4 COMPANYWISE VAD NUMBER OF UNITS SOLD (2020) 123
3.17 COMPARISON OF CARDIAC ASSIST DEVICES 123
4 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PRODUCT 131
4.1 INTRODUCTION 131
4.2 VENTRICULAR ASSIST DEVICES (VAD) 135
4.2.1 LEFT VENTRICULAR ASSIST DEVICES (LVAD) 143
4.2.2 RIGHT VENTRICULAR ASSIST DEVICES (RVAD) 145
4.2.3 BI-VENTRICULAR ASSIST DEVICES (BI-VAD) 147
4.3 INTRA-AORTIC BALLOON PUMPS (IABP) 149
4.4 TOTAL ARTIFICIAL HEART (TAH) 150
5 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY IMPLANT TYPE 153
5.1 INTRODUCTION 153
5.2 EXTRACORPOREAL OR PARACORPOREAL CAD 155
5.3 INTRACORPOREAL CAD 157
5.4 PERCUTANEOUS CAD 159
6 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PUMP TYPE 162
6.1 INTRODUCTION 162
6.2 PULSATILE FLOW PUMP 165
6.3 CONTINUOUS FLOW PUMP 167
6.3.1 CENTRIFUGAL FLOW PUMP 171
6.3.2 AXIAL FLOW PUMP 173
7 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY PATIENT TYPE 175
7.1 INTRODUCTION 175
7.2 PEDIATRIC CAD 177
7.3 ADULT CAD 180
8 CARDIAC ASSIST DEVICES GLOBAL MARKET, BY APPLICATION 182
8.1 INTRODUCTION 182
8.2 CAD TREATMENT FLOW CHART 185
8.3 BRIDGE TO TRANSPLANT (BTT) 187
8.4 BRIDGE TO DESTINATION THERAPY (BTD) 188
8.5 BRIDGE TO RECOVERY (BTR) 190
8.6 BRIDGE TO CANDIDACY (BTC) 191
9 REGIONAL ANALYSIS 193
9.1 INTRODUCTION 193
9.2 NORTH AMERICA 196
9.2.1 THE U.S. 211
9.2.2 REST OF NORTH AMERICA 216
9.3 EUROPE 220
9.3.1 GERMANY 237
9.3.2 FRANCE 242
9.3.3 U.K. 246
9.3.4 REST OF EUROPE 250
9.4 APAC 255
9.4.1 JAPAN 271
9.4.2 CHINA 276
9.4.3 INDIA 281
9.4.4 REST OF APAC 286
9.5 ROW 291
9.5.1 BRAZIL 307
9.5.2 REST OF LATIN AMERICA 311
9.5.3 MIDDLE EAST AND OTHERS 316
10 COMPANY DEVELOPMENTS 321
10.1 INTRODUCTION 321
10.2 APPROVALS 322
10.3 AGREEMENTS AND JOINT VENTURES 324
10.4 OTHER DEVELOPMENTS 324
11 MAJOR COMPANIES 326
11.1 ABBOTT LABORATORIES 326
11.1.1 OVERVIEW 326
11.1.2 FINANCIALS 327
11.1.3 PRODUCT PORTFOLIO 329
11.1.4 KEY DEVELOPMENTS 330
11.1.5 BUSINESS STRATEGY 330
11.1.6 SWOT ANALYSIS 331
11.2 ABIOMED, INC. 332
11.2.1 OVERVIEW 332
11.2.2 FINANCIALS 333
11.2.3 PRODUCT PORTFOLIO 334
11.2.4 KEY DEVELOPMENTS 334
11.2.5 BUSINESS STRATEGY 335
11.2.6 SWOT ANALYSIS 336
11.3 BERLIN HEART GMBH 337
11.3.1 OVERVIEW 337
11.3.2 FINANCIALS 337
11.3.3 PRODUCT PORTFOLIO 338
11.3.4 KEY DEVELOPMENTS 338
11.3.5 BUSINESS STRATEGY 339
11.3.6 SWOT ANALYSIS 340
11.4 FRESENIUS MEDICAL CARE AG & CO. KGAA (XENIOS AG) 341
11.4.1 OVERVIEW 341
11.4.2 FINANCIALS 342
11.4.3 PRODUCT PORTFOLIO 343
11.4.4 KEY DEVELOPMENTS 344
11.4.5 BUSINESS STRATEGY 344
11.4.6 SWOT ANALYSIS 345
11.5 GETINGE GROUP (MAQUET) 346
11.5.1 OVERVIEW 346
11.5.2 FINANCIALS 347
11.5.3 PRODUCT PORTFOLIO 348
11.5.4 KEY DEVELOPMENTS 349
11.5.5 BUSINESS STRATEGY 349
11.5.6 SWOT ANALYSIS 350
11.6 LIVANOVA PLC 351
11.6.1 OVERVIEW 351
11.6.2 FINANCIALS 352
11.6.3 PRODUCT PORTFOLIO 354
11.6.4 KEY DEVELOPMENTS 354
11.6.5 BUSINESS STRATEGY 355
11.6.6 SWOT ANALYSIS 356
11.7 MEDTRONIC, PLC 357
11.7.1 OVERVIEW 357
11.7.2 FINANCIALS 358
11.7.3 PRODUCT PORTFOLIO 361
11.7.4 KEY DEVELOPMENTS 362
11.7.5 BUSINESS STRATEGY 362
11.7.6 SWOT ANALYSIS 363
11.8 SYNCARDIA SYSTEMS, LLC 364
11.8.1 OVERVIEW 364
11.8.2 FINANCIALS 365
11.8.3 PRODUCT PORTFOLIO 365
11.8.4 KEY DEVELOPMENTS 365
11.8.5 BUSINESS STRATEGY 365
11.8.6 SWOT ANALYSIS 366
11.9 TELEFLEX INCORPORATED 367
11.9.1 OVERVIEW 367
11.9.2 FINANCIALS 368
11.9.3 PRODUCT PORTFOLIO 371
11.9.4 KEY DEVELOPMENTS 371
11.9.5 BUSINESS STRATEGY 371
11.9.6 SWOT ANALYSIS 372
11.10 ZEON CORPORATION 373
11.10.1 OVERVIEW 373
11.10.2 FINANCIALS 374
11.10.3 PRODUCT PORTFOLIO 376
11.10.4 KEY DEVELOPMENTS 376
11.10.5 BUSINESS STRATEGY 377
11.10.6 SWOT ANALYSIS 378
Related Report
